Geoffrey von Maltzahn
Geoffrey von Maltzahn joined Flagship Pioneering in 2009 and serves as general partner. He is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies in healthcare and agriculture.
Geoffrey has co-founded companies that have, in aggregate, achieved over $9 billion in public and private market capitalization. Through his role in Flagship Labs, the companies Geoffrey has created include Tessera Therapeutics, Generate Biomedicines, Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences (NASDAQ: KLDO), Seres Therapeutics (NASDAQ: MCRB), and Axcella Health (NASDAQ: AXLA) which are, respectively, pioneering gene writing; generative biology; plant microbiome products for crop improvement; engineered cells and cell-specific gene therapies; novel chemistries to drive the human microbiome; the first microbiome therapeutics; and amino acid-based drugs.
Geoffrey currently serves as chief executive officer of Tessera Therapeutics and Generate Biomedicines and , chief innovation officer and director of Indigo, and director of Kaleido Biosciences and Sana Biotechnology. He recently served as chief executive officer of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology, as Kaleido’s chief executive officer, where he led the company from inception to launching multiple clinical studies, and Indigo’s chief executive officer, where he led the development of the company's plant microbiome platform and the discovery of the company's first commercial products: Indigo Cotton, Indigo Wheat, Indigo Corn, and Indigo Soy. Previously, Geoffrey was the chief technology officer of Seres Therapeutics (NASDAQ: MCRB), where he led the discovery of SER-109, the first microbiome therapeutic to report positive phase 3 data, and built out the company’s discovery platform.
Geoffrey has deep expertise in the genome engineering, microbiome, bioengineering, and nanotechnology, and he has been recognized with numerous patent grants, awards, and publications. He is an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed publications. Geoffrey has received a number of awards and honors, including: Business Insider’s 30 Biotech Leaders Under 40; Endpoints top 20 leaders under 40; Boston Chamber of Commerce Ten Outstanding Young Leaders; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative student at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; and the Harvard-MIT Martha Gray Prize. Geoffrey and his inventions have been profiled by Forbes, the Economist, CNN, Scientific American, Popular Science, MIT Technology Review, and others.
Geoffrey was awarded a Ph.D. in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, M.D., Ph.D.; a M.S. in bioengineering from the University of California, San Diego; and a S.B. in chemical engineering from MIT.